16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

ACI-24: Phase Ib start

This quarter, AC Immune will begin a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate subcutaneous ACI-24 for 12 months in 24 adults with Down syndrome. The trial is funded by NIH and the LuMind...
01:59 , Jan 10, 2014 |  BC Extra  |  Financial News

Alzheimer's play AC Immune secures $22.1 million

AC Immune S.A. (Lausanne, Switzerland) secured CHF20 million ($22.1 million) in a tranched series D round from undisclosed existing private investors. Also on Thursday, AC Immune announced that it began a Phase I trial to...
07:00 , May 9, 2013 |  BC Innovations  |  Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Pirenzepine: Development discontinued

AC Immune discontinued development of ACI-91 after top-line data from a double-blind, placebo-controlled, German and Austrian Phase II trial in 63 patients with mild to moderate AD showed that twice-daily 75 mg ACI-91 for 12...
08:00 , Dec 17, 2012 |  BioCentury  |  Emerging Company Profile

Alzinova: Freezing out AD

Alzinova AB is developing an Alzheimer's disease vaccine that uses an engineered beta amyloid mimic to raise an immune response against highly toxic AD-associated beta amyloid oligomers. The approach could yield a more potent protective...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

AD pipeline: Immunotherapies

AD pipeline: Immunotherapies Company Product Description Status Baxter International Inc. (NYSE:BAX) Gammagard Liquid 10% Plasma-based therapy containing IgG antibodies Ph III Eli Lilly and Co. (NYSE:LLY)...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Company News

AC Immune, Bayer deal

AC Immune will use Bayer's labeled tracer florbetaben to support an ongoing Phase I trial of AC Immune's ACI-24 Alzheimer's disease vaccine. Bayer's Bayer Schering Pharma AG subsidiary will provide the positron emission...